

Shoji Takakura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4884181/publications.pdf>

Version: 2024-02-01

10
papers

116
citations

1478505

6
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

196
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute and Direct Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glomerular Filtration Rate in Spontaneously Diabetic Torii Fatty Rats. <i>Biological and Pharmaceutical Bulletin</i> , 2019, 42, 1707-1712.	1.4	4
2	Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy. <i>Life Sciences</i> , 2019, 230, 19-27.	4.3	22
3	<i>In Vitro</i> Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-transporter 2 Inhibitor. <i>Biological and Pharmaceutical Bulletin</i> , 2019, 42, 507-511.	1.4	10
4	First-dose effect of the SGLT2 inhibitor ipragliflozin on cardiovascular activity in spontaneously diabetic Torii fatty rats. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019, 46, 266-273.	1.9	3
5	Protective Effect of Ipragliflozin on Pancreatic Islet Cells in Obese Type 2 Diabetic db/db Mice. <i>Biological and Pharmaceutical Bulletin</i> , 2018, 41, 761-769.	1.4	9
6	The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats. <i>Biological and Pharmaceutical Bulletin</i> , 2017, 40, 675-680.	1.4	8
7	Functional imaging of pharmacological action of SGLT 2 inhibitor ipragliflozin via PET imaging using ¹¹ C-MD–MDC. <i>Pharmacology Research and Perspectives</i> , 2016, 4, e00244.	2.4	7
8	A chronic renal rejection model with a fully MHC-mismatched rat strain combination under immunosuppressive therapy. <i>Transplant Immunology</i> , 2016, 38, 19-26.	1.2	3
9	Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats. <i>Life Sciences</i> , 2016, 147, 125-131.	4.3	43
10	Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2015, 42, 87-93.	1.9	7